Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of iptacopan in atypical hemolytic uremic syndrome (aHUS)
jRCT2031250834Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoint: Safety evaluations. Started May 2026; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on jRCT2031250834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250834.